InsiderTrades

Form 4 for LXEO Lexeo Therapeutics, Inc.

Accepted 2023-11-09 00:00:00 ET · period of report 2023-11-07 · accession 0001209191-23-054907 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-11-09 2023-11-07 LXEO Lundbeckfond Invest A/S 10% C - Cnv Deriv — +1.61M 1.32M New —
D 2023-11-09 2023-11-07 LXEO Lundbeckfond Invest A/S 10% P - Purchase $11.00 +227.3K 1.84M +14% +$2.50M
DM 2023-11-09 2023-11-07 LXEO Lundbeckfond Invest A/S 10% C - Cnv Deriv — -16.62M 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-11-07 C A 287,213 — 1,608,687 D — — (F2) Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
2 Common Common Stock 2023-11-07 C A 1,321,474 — 1,321,474 D — — (F1) Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.
3 Common Common Stock 2023-11-07 P A 227,272 $11.00 1,835,959 D — —
4 Derivative Series B convertible preferred stock 2023-11-07 C D 2,615,533 — 0 D — · — to — 287,213 Common Stock (F2) Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
5 Derivative Series A convertible preferred stock 2023-11-07 C D 13,999,999 — 0 D — · — to — 1,321,474 Common Stock (F1) Upon the closing of the Issuer's initial public offering, each share of Series A convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-10.594230 basis. The shares had no expiration date.